MONTREAL, May 11 /PRNewswire/ - Immucon announces that it is now offering the detection of protein P34H on the surface of the sperm through all fertility centers and andrology labs located in North America. A recent study involving three fertility centers and which results are being published this month in Fertility & Sterility, reveals that the lack of protein P34H on the sperm can be used as a predictor of cases of failed fertilization treatments.
Male origin infertility accounts for 40-50% of all cases of infertility. When searching for male infertility factors, infertile couples should definitely include the detection of sperm protein P34H on their list of male tests. Past research has shown that the lack of protein P34H on the sperm is linked to a significant number of male infertility cases. According to the data collected in the laboratory of Dr. Robert Sullivan, PhD, out of 138 cases of infertility screened for protein P34H, 46 exhibited a protein P34H deficiency. On the other side, 80 couples with proven fertility also screened for protein P34H, all had normal levels of sperm protein P34H.
Lack of protein P34H has previously provided an explanation for cases of vasectomy reversal where fertility is not recovered. According to the results published in the Journal of Andrology, men who undergo a vasectomy reversal operation can lack protein P34H, especially if the period of time since the vasectomy is long.
15% of all couples attempting to have a child are affected by infertility. Problems are usually minor for half of these couples. However, the other half will require a specialized IVF treatment from a fertility centre to fulfill their desire. The early identification of a male factor of infertility such as the lack of protein P34H on the surface of the sperm allows fertility specialists to orient their patients towards the best possible treatment.
IMMUCON
CONTACT: Mr. Alain Bosse, president, IMMUCON, (514) 878-1591, 1 888435-7918, abosse@immucon.com, www.immucon.com